Clinical trial NCT06643897: Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina.
Official title: Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina as an Optional Therapy in People Living With HIV From Spain.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV-1-infection
Keywords: barriers and facilitators
interview
long acting
out-of-hospital by implementation
cabotegravir + rilpivirine (CAB+RPV)
HIV-1
Lead sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Sponsor class: OTHER
First posted: 2024-10-16
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The substudy is a transversal, one arm, multicentric study including the staff participating in the HOLA study, to identify the barriers and facilitators of implementation of the out-of-hospital administration of CAB+RPV LA following a qualitative descriptive design.

All study staff who participate in the substudy will be interviewed through a 40-50 minute-qualitative interview
Primary purpose: OTHER

Brief summary: The study will identify the barriers and facilitators of implementation of the out-of-hospital administration of CAB+RPV LA from the point of view of staff participating in the study.

Detailed description: This substudy will use a qualitative descriptive approach based on Consolidated Framework for Implementation Research (CFIR). Data will be collected using semi-structured interviews among HOLA staff participants until achieving data saturation. Data will be analyzed using Braun \&amp; Clarke\&#39;s thematic analysis method.

Eligibility criteria: Inclusion Criteria:

1. Participation throughout the HOLA study until the moment of conducting the interviews and direct involvement in the study procedures in a significant way.
2. Homogeneous sample between the different roles participating in the study.
3. Participants who agree to participate in the substudy and sign the informed consent.

Exclusion Criteria: NONE

Primary outcomes:
measure: Identify the barriers and facilitators of implementation of the out-of-hospital administration of CAB+RPV LA from the point of view of staff participating in the study.
timeFrame: after the first 6 months of participation in the study
Secondary outcomes:
Other outcomes:
Locations:
city: Badalona
country: Spain
facility: Germans Trias I Pujol Hospital
state: Barcelona
city: Barcelona
country: Spain
facility: CAP Dr Robert
city: Barcelona
country: Spain
facility: Centre de Salut Internacional i Malalties Transmissibles Drassanes - Vall d'Hebron
city: Barcelona
country: Spain
facility: BCN CheckPoint
city: Barcelona
country: Spain
facility: Hospital Vall D' Hebrón
city: Málaga
country: Spain
facility: Cs Leganitos
city: Málaga
country: Spain
facility: Hospital Costa Del Sol
city: Málaga
country: Spain
facility: Cs San Luis de Sabinillas
city: Málaga
country: Spain
facility: Cs San Pedro de Alcántara
Study officials:
References: